A study to learn about the long-term safety and efficacy of giroctocogene fitelparvovec or fidanacogene elaparvovec in patients with hemophilia A or hemophilia B respectively, who have received treatment through prior participation in a Pfizer-sponsored clinical trial. Data collection and participant visits will be based on standard of care.
See this in plain English?
AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.
Incidence of thromboembolic events
Timeframe: Day 1 to 10 years
Incidence of factor inhibitor development
Timeframe: Day 1 to 10 years
Incidence of hepatic malignancy
Timeframe: Day 1 to 10 years
Incidence of liver abnormalities
Timeframe: Day 1 to 10 years
Factor activity level
Timeframe: Day 1 to 10 years
Pfizer CT.gov Call Center